Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma.

Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma. J Natl Compr Canc Netw. 2019 May 01;17(5.5):615-617 Authors: Olszanski AJ Abstract According to Dr. Anthony J. Olszanski, the most significant updates to the treatment of cutaneous melanoma include the recently published results of MSLT-II, which demonstrated that ultrasound-guided follow-up can be performed rather than a complete lymph node dissection, improving morbidity in patients with sentinel node metastases while not adversely affecting survival. In the adjuvant setting, the PD-1 inhibitors nivolumab and pembrolizumab are now FDA-approved, in addition to dabrafenib and trametinib, for patients with BRAF mutations. PMID: 31117032 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research